Palo Alto, Calif.-based Varian said that Noona developed a cloud-based mobile service intended to capture cancer patient-reported outcomes. The system allows clinics to capture PROs and communicate with patients, the company added.
“PROs represent a growing and significant metric in evidence-based clinical care and translational research. With this acquisition, Varian gains new partnerships with life-sciences and pharma companies as the Noona software app is used to engage patients, collect PRO data, manage patient communications and enable clinical studies that will test the efficacy of treatment modalities when treating cancer,” Varian prez & CEO Dow Wilson said in a press release.
Varian said that the acquisition will expand its cancer care solutions portfolio, and that the acquisition fits into its long-term growth and value creation strategy.
“We are excited to add the Noona technology and team to Varian as we continue to become a global leader in multi-disciplinary integrated cancer care solutions, focused on improving patient care. This acquisition adds smart mobile technology to Varian’s cloud-based software portfolio. It will allow oncologists to capture real-time PROs and monitor and proactively manage their patient’s symptoms. Sustained engagement with patients may help oncologists detect early signs of potential recurrence or progression of metastatic disease,” Varian oncology software solutions senior VP Corey Zankowski said in a prepared statement.
The company said it plans to combine its 360 oncology SaaS platform with Noona’s patient user interface, and to expand Noona’s portfolio of real-world, evidence-driven services.
“The combination of the Noona software app with Varian’s 360 Oncology is a natural fit. With this acquisition, we have the opportunity to expand the global availability of the Noona technology to the clinical community and elevate the voice of the patient in their cancer care,” Noona CEO Jani Ahonala said in prepared remarks.
In August, Varian said that it acquired privately-held HumediQ, which develops the Identify automated patient identification, positioning and management system for radiation therapy, for an undisclosed amount.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.